185 related articles for article (PubMed ID: 7651435)
1. Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators.
Chang CC; Zhang J; Lombardi L; Neri A; Dalla-Favera R
Mol Cell Biol; 1995 Sep; 15(9):5180-7. PubMed ID: 7651435
[TBL] [Abstract][Full Text] [Related]
2. Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts.
Ciana P; Neri A; Cappellini C; Cavallo F; Pomati M; Chang CC; Maiolo AT; Lombardi L
Oncogene; 1997 Apr; 14(15):1805-10. PubMed ID: 9150386
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of expression and role in transcriptional control of the proto-oncogene NFKB-2/LYT-10.
Chang CC; Zhang J; Lombardi L; Neri A; Dalla-Favera R
Oncogene; 1994 Mar; 9(3):923-33. PubMed ID: 8108136
[TBL] [Abstract][Full Text] [Related]
4. The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies.
Neri A; Fracchiolla NS; Migliazza A; Trecca D; Lombardi L
Leuk Lymphoma; 1996 Sep; 23(1-2):43-8. PubMed ID: 9021684
[TBL] [Abstract][Full Text] [Related]
5. Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions.
Zhang J; Chang CC; Lombardi L; Dalla-Favera R
Oncogene; 1994 Jul; 9(7):1931-7. PubMed ID: 8208540
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies.
Migliazza A; Lombardi L; Rocchi M; Trecca D; Chang CC; Antonacci R; Fracchiolla NS; Ciana P; Maiolo AT; Neri A
Blood; 1994 Dec; 84(11):3850-60. PubMed ID: 7949142
[TBL] [Abstract][Full Text] [Related]
7. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50.
Neri A; Chang CC; Lombardi L; Salina M; Corradini P; Maiolo AT; Chaganti RS; Dalla-Favera R
Cell; 1991 Dec; 67(6):1075-87. PubMed ID: 1760839
[TBL] [Abstract][Full Text] [Related]
8. Heterologous C-terminal sequences disrupt transcriptional activation and oncogenesis by p59v-rel.
Diehl JA; Hannink M
J Virol; 1993 Dec; 67(12):7161-71. PubMed ID: 8230438
[TBL] [Abstract][Full Text] [Related]
9. Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies.
Fracchiolla NS; Lombardi L; Salina M; Migliazza A; Baldini L; Berti E; Cro L; Polli E; Maiolo AT; Neri A
Oncogene; 1993 Oct; 8(10):2839-45. PubMed ID: 8378093
[TBL] [Abstract][Full Text] [Related]
10. Molecular cloning and characterization of a novel Rel/NF-kappa B family member displaying structural and functional homology to NF-kappa B p50/p105.
Mercurio F; Didonato J; Rosette C; Karin M
DNA Cell Biol; 1992 Sep; 11(7):523-37. PubMed ID: 1388725
[TBL] [Abstract][Full Text] [Related]
11. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.
Dechend R; Hirano F; Lehmann K; Heissmeyer V; Ansieau S; Wulczyn FG; Scheidereit C; Leutz A
Oncogene; 1999 Jun; 18(22):3316-23. PubMed ID: 10362352
[TBL] [Abstract][Full Text] [Related]
12. Overproduction of NFKB2 (lyt-10) and c-Rel: a mechanism for HTLV-I Tax-mediated trans-activation via the NF-kappa B signalling pathway.
Lanoix J; Lacoste J; Pepin N; Rice N; Hiscott J
Oncogene; 1994 Mar; 9(3):841-52. PubMed ID: 8108127
[TBL] [Abstract][Full Text] [Related]
13. Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of kappa B enhancer-binding proteins: evidence for a pretranslational component of regulation.
Arima N; Molitor JA; Smith MR; Kim JH; Daitoku Y; Greene WC
J Virol; 1991 Dec; 65(12):6892-9. PubMed ID: 1719236
[TBL] [Abstract][Full Text] [Related]
14. The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding.
Hatada EN; Nieters A; Wulczyn FG; Naumann M; Meyer R; Nucifora G; McKeithan TW; Scheidereit C
Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2489-93. PubMed ID: 1532257
[TBL] [Abstract][Full Text] [Related]
15. NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule.
Scheinman RI; Beg AA; Baldwin AS
Mol Cell Biol; 1993 Oct; 13(10):6089-101. PubMed ID: 8413211
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the human P-selectin promoter by Bcl-3 and specific homodimeric members of the NF-kappa B/Rel family.
Pan J; McEver RP
J Biol Chem; 1995 Sep; 270(39):23077-83. PubMed ID: 7559449
[TBL] [Abstract][Full Text] [Related]
17. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner.
Nolan GP; Fujita T; Bhatia K; Huppi C; Liou HC; Scott ML; Baltimore D
Mol Cell Biol; 1993 Jun; 13(6):3557-66. PubMed ID: 8497270
[TBL] [Abstract][Full Text] [Related]
18. Functional synergism of STAT6 with either NF-kappa B or PU.1 to mediate IL-4-induced activation of IgE germline gene transcription.
Stütz AM; Woisetschläger M
J Immunol; 1999 Oct; 163(8):4383-91. PubMed ID: 10510379
[TBL] [Abstract][Full Text] [Related]
19. I kappa B alpha can localize in the nucleus but shows no direct transactivation potential.
Cressman DE; Taub R
Oncogene; 1993 Sep; 8(9):2567-73. PubMed ID: 8361766
[TBL] [Abstract][Full Text] [Related]
20. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.
Cogswell PC; Guttridge DC; Funkhouser WK; Baldwin AS
Oncogene; 2000 Feb; 19(9):1123-31. PubMed ID: 10713699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
